Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525589 · ClinicalTrials.gov registry record · Phase 2
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Phase 2 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT01525589 is a Phase 2 study that has completed, run by PharmaMar. The registered enrollment target is 111 participants.
The verdict
NCT01525589, a Phase 2 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.
Interventions
- DRUG PM01183
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2012-06-13 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525589
The ClinicalTrials.gov registry entry for NCT01525589 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PM01183 is the first listed.
NCT01525589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525589 about?
NCT01525589 is a clinical study titled "A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer". A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to an...
What is the current status of trial NCT01525589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2012-06-13. Estimated completion is 2018-10.
What interventions are being tested in trial NCT01525589?
The interventions under investigation include: PM01183 (DRUG).
Who is sponsoring clinical trial NCT01525589?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.